Alkermes PLC - (ALKS) closed at $46.17 on November 9, 2026, up 0.6% from the previous close, on volume of 1,583,108 shares (30-day average 1,935,579).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Diagonal Put Spread | 16-Oct : 20-Nov-2644 : 37 P | 3,252 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Thu, 5-Nov 7:00 AM ET)
TipRanks (Wed, 4-Nov 3:50 PM ET)
RBC Capital Keeps Their Buy Rating on Alkermes (ALKS)
TipRanks (Wed, 4-Nov 8:57 AM ET)
TipRanks (Wed, 4-Nov 8:20 AM ET)
Alkermes to Present at Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 4:00 PM ET)
Alkermes sets an 8:00 a.m. ET call as it reports Q3 2026 results
Market Chameleon (Tue, 3-Nov 4:22 AM ET)
Alkermes plc Reports Third Quarter 2026 Financial Results
Business Wire (Tue, 3-Nov 7:05 AM ET)
Business Wire (Fri, 30-Oct 7:00 AM ET)
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Business Wire (Tue, 20-Oct 4:00 PM ET)
Business Wire (Tue, 13-Oct 7:00 AM ET)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Alkermes PLC - trades on the NASDAQ stock market under the symbol ALKS.
As of November 9, 2026, ALKS stock price climbed to $46.17 with 1,583,108 million shares trading.
ALKS has a beta of 0.06, meaning it tends to be less sensitive to market movements. ALKS has a correlation of 0.00 to the broad based SPY ETF.
ALKS has a market cap of $7.75 billion. This is considered a Mid Cap stock.
Last quarter Alkermes PLC - reported $480 million in Revenue and $.09 earnings per share. This beat revenue expectation by $16 million and missed earnings estimates by -$.09.
In the last 3 years, ALKS traded as high as $55.67 and as low as $22.06.
The top ETF exchange traded funds that ALKS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.
ALKS has outperformed the market in the last year with a price return of +45.7% while the SPY ETF gained +13.4%. However, in the short term, ALKS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -4.5% vs -1.8% return in SPY. But in the last 2 weeks, ALKS shares have fared better than the market returning +5.8% compared to SPY -1.0%.
ALKS support price is $44.80 and resistance is $47.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALKS shares will trade within this expected range on the day.
